Study S000591

Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

ClinicalTrials.gov record

Registration

Registration: NCT03492580
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 714582
Start: 2018-02-22
Primary completion: 2018-04-06
Lead sponsor: Janssen Research & Development, LLC
Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases
Interventions: DRUG:Canagliflozin; DRUG:Empagliflozin; DRUG:Dapagliflozin; DRUG:Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; DRUG:Glucagon-like Peptide-1 (GLP-1) Agonist; DRUG:Anti-hyperglycemic Agents (AHA); DRUG:Thiazolidinediones (TZD); DRUG:Sulfonylureas (SU); DRUG:Insulin
Results posted: FALSE
Secondary identifiers: OTHER:RRA-20250

Registered primary outcomes

Number of Hospitalizations for Heart Failure [Approximately 4-years]
Number of Participants with Below Knee Lower Extremity Amputation Events [Approximately 4-years]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.